What is the 40-GEP test?
Clinical Professor of Dermatology
Director, Melanoma Surveillance Clinic
Mount Sinai Icahn School of Medicine, New York, NY
Adjunct Professor, UT Southwestern Medical School
Consultant Dermatologist, Cooper Clinic, Dallas, TX
The 40-GEP test is a test using gene expression profiles to assess prognosis with squamous cell carcinoma. It's a new approach and the advantage is, in the past we've used clinical histologic factors to try to assess prognosis, this gives us an extra dimension using genomics to better assess prognosis.
In the video, Dr. Darrell Rigel explains that the 40-GEP test is a new approach to assess prognosis with squamous cell carcinoma. The test utilizes gene expression profiles (genomics) to provide additional information beyond traditional clinical and histologic factors. By incorporating genomics, the 40-GEP test offers an extra dimension to better evaluate the prognosis of patients with squamous cell carcinoma, potentially leading to more accurate and personalized treatment decisions.
- The 40-GEP test is a test that utilizes gene expression profiles to assess prognosis in cases of squamous cell carcinoma.
- It represents a new approach in contrast to the traditional method of using clinical and histologic factors to determine prognosis.
- The test offers an advantage by introducing genomics as an additional dimension to improve the accuracy of prognosis assessment.
- The term "40-GEP" refers to the specific gene expression profile that is analyzed in the test.
- By incorporating genomic information, the 40-GEP test aims to provide a more comprehensive and precise evaluation of the prognosis for squamous cell carcinoma patients.